Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTO-104 Safety Study in Meniere's Disease
NCT02740387Phase 2Terminated
- Sponsor
- Otonomy, Inc.
- Start
- Jun 2016
- Primary completion
- Sep 2017
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Otividex in Meniere's disease (MD), sponsored by Otonomy, Inc.. Started Jun 2016; status: terminated.
02
Drugs
Otividex
03
Conditions
Meniere's disease (MD)
Beyond the preview
Go deeper on NCT02740387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02740387.